- 1 Genome-wide association studies of thyroid-related hormones,
- 2 dysfunction, and autoimmunity among 85,421 Chinese
- 3 pregnancies

7

1516

- 5 Yuandan Wei<sup>1,2#</sup>, Jianxin Zhen<sup>2#</sup>, Liang Hu<sup>3#</sup>, Yuqin Gu<sup>1</sup>, Yanhong Liu<sup>1</sup>, Xinxin Guo<sup>1</sup>, Zijing Yang<sup>1</sup>,
- 6 Hao Zheng<sup>1</sup>, Shiyao Cheng<sup>1</sup>, Fengxiang Wei<sup>3\*</sup>, Likuan Xiong<sup>2,4\*</sup>, Siyang Liu<sup>1\*</sup>
- 8 1. School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen,
- 9 Guangdong 518107, China
- 10 2. Central Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong
- 11 518102, China
- 12 3. Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Longgang Maternity
- and Child Institute of Shantou University Medical College), Shenzhen, Guangdong 518172, China
- 4. Shenzhen Key Laboratory of Birth Defects Research, Shenzhen, Guangdong 518102, China
- 17 # Those authors contribute equally
- 18 \*: Correspondence should be addressed to
- 19 Siyang Liu <u>liusy99@mail.sysu.edu.cn</u>
- 20 Likuan Xiong xionglk@sina.cn
- 21 Fengxiang Wei haowei727499@163.com

**Abstract** 

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Maintaining normal thyroid function is crucial in pregnancy, yet thyroid dysfunction and the presence of thyroid peroxidase antibodies (TPOAb) affect 0.5% to 18% of pregnant women. Here, we conducted a genome-wide association study (GWAS) of eight thyroid traits, including two thyroid-related hormones, four thyroid dysfunctions, and two thyroid autoimmunity measurements among 85,421 Chinese pregnant women to investigate the genetic basis of thyroid function during pregnancy. Our study identified 176 genetic loci, including 125 previously unknown genome-wide associations. Joint epidemiological and Mendelian randomization analyses revealed significant associations between the gestational thyroid phenotypes and gestational complications, birth outcomes, and later-age health outcomes. Specifically, genetically elevated thyroid-stimulating hormone (TSH) levels during pregnancy correlated with lower glycemic levels, reduced blood pressure, and longer gestational duration. Additionally, TPOAb and thyroid functions during pregnancy share genetic correlations with later-age thyroid and cardiac disorders. These findings provide novel insights into the genetic determinants of thyroid traits during pregnancy, which may lead to new therapeutics, early pre-diagnosis and preventive strategies starting from early adulthood.

Introduction

86

46 47 Pregnancy represents a crucial phase in human reproduction, impacting both maternal 48 and offspring health. Particularly, normal maternal thyroid function and lack of 49 autoimmunity during pregnancy, commonly assessed by measuring circulating thyroid-stimulating hormone (TSH), free thyroxine (FT4) levels, and presence and 50 51 quantification of thyroid peroxidase antibodies (TPOAb), holds significant relevance for pregnancy outcomes and long-term health<sup>[1,2]</sup>. Thyroid dysfunctions during 52 pregnancy are determined by these measurements and demonstrate varying 53 54 prevalence, ranging from 0.5% for overt hypothyroidism (defined as elevated TSH levels and low free T4 concentrations) to 3.47% for subclinical hypothyroidism 55 (defined as elevated TSH levels with normal FT4 concentrations)<sup>[3]</sup>, and 18% for 56 thyroid autoimmunity<sup>[2]</sup>. Observationally epidemiologic studies have consistently 57 linked abnormal thyroid function tests during pregnancy to adverse maternal and 58 infant outcomes, including preterm birth<sup>[4]</sup>, low birth weight<sup>[5]</sup>, miscarriage, and 59 preeclampsia<sup>[6]</sup>. However, the underlying biological mechanisms controlling the 60 population variability of TSH, FT4, TPOAb, and thyroid dysfunctions during 61 62 pregnancy, and their potential causal relationships with pregnancy and long-term 63 health outcomes remain unclear. 64 65 Previous research indicates that a significant portion of the inter-individual variability in thyroid hormone levels among general populations can be attributed to genetics. 66 67 Twin and family studies estimate heritable contributions to approximately 64%-70.8% for serum TSH, 39%-80% for FT4<sup>[7-9]</sup>, and 48.8% for anti-thyroid peroxidase 68 antibody (TPOAb)<sup>[9]</sup>. Large-scale meta-genome-wide association studies of thyroid 69 hormones among general European populations have identified lead SNPs explaining 70 22.8% of TSH variation and 4% of FT4 variation, respectively<sup>[10,11]</sup>. These studies 71 72 suggest that genetics may also influence thyroid function measurements during 73 gestation, an aspect that has been under-studied. Notably, unlike thyroid functions 74 outside the pregnancy period, changes in the hormonal environment during pregnancy 75 lead to more complex alterations in a woman's thyroid function. Maternal demand for thyroid rises during pregnancy due to fetal use of thyroid hormones and an increase in 76 thyroxine-binding globulin (TBG), among other reasons<sup>[12]</sup>. In particular, human 77 78 chorionic gonadotrophin (hCG), which is structurally similar to TSH, significantly 79 increases in early pregnancy, leading to higher thyroid hormone production, 80 eventually resulting in decreased TSH levels under negative feedback regulation eventually<sup>[13]</sup>. Therefore, GWAS studies based on pregnant women may not be 81 82 extrapolated from studies on general adults, and would greatly enhance our 83 understanding of the genetic basis of thyroid-related traits throughout life. However, 84 very few GWAS on thyroid-related traits have included pregnant women. To date, 85 only one candidate gene study that involved 974 healthy pregnant women, reported an

association between the number of TSH-raising alleles and subclinical

89

90 91 92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112113

114

115

116

117

118

119

120

121

122

123

124

125

hypothyroidism in pregnancy<sup>[14]</sup>. In addition, the association between subclinical dysfunction and pregnancy outcomes, as well as the efficacy of treating mild abnormalities, remains uncertain and controversial owing to the lack of robust causal evidence<sup>[15,16]</sup>. To elucidate the genetic factors influencing thyroid function and disorders during pregnancy, and their potential causal impact on pregnancy complications, birth outcomes, and later-age physical conditions, we conducted a genome-wide association and Mendelian randomization study among 85,421 Chinese pregnant participants with non-invasive prenatal test (NIPT) sequencing data, comprehensive pregnancy screening and medical records from two hospitals in China. We focused on the most commonly used thyroid biomarkers in pregnancy assessments, including thyroid-stimulating hormone (TSH) and free thyroxine (FT4), and thyroid autoimmunity measurements such as anti-thyroid peroxidase antibody (TPOAb) levels and positivity. Additionally, we examined four clinical or subclinical thyroid statuses, including subclinical hypothyroidism (SHO), isolated hypothyroxinemia (ISH), overt hyperthyroidism (OHP), subclinical hyperthyroidism (SHP). **Results** Study design and demographic characteristics Our study design and analysis scheme are depicted in **Figure 1**. Briefly, we enrolled pregnant women during routine pregnancy screening at two maternal and child healthcare hospitals – abbreviated as Longgang and Baoan hospitals, located in Shenzhen, a metropolitan city in southern China. We imputed genotypes and examined population structure from non-invasive prenatal test sequencing data following a standardized protocol developed by our laboratory<sup>[17,18]</sup>. We conducted GWAS analyses for 2 thyroid-related hormones (TSH and FT4) within reference ranges, 4 thyroid dysfunctions (subclinical hypothyroidism, isolated hypothyroxinemia, subclinical hyperthyroidism, and overt hyperthyroidism), and 2 thyroid autoimmunity traits (TPOAb levels and TPOAb positivity) for each of the two hospitals, followed by a fixed-effect meta-analysis across 12.7 million SNPs (Methods). Subsequently, phenotypic association and Mendelian randomization analyses were used to investigate the relationships between these eight traits, gestational complications such as gestational diabetes mellitus (GDM), birth outcomes, and later-life physical conditions using summary statistics from GWAS. Since TSH and FT4 have been investigated in prior GWAS studies in the general population, we further conducted conditional analyses to identify potential novel association signals within the established loci for these two traits. We evaluated the GWAS results by examining the consistency of effect size estimates between the two

127

128

129

130131

132

133

134

135

136

137

138

139

140

141

142143144

145

146147

148

149

150

151

152

153154

155

156

157

158

159

160

161

162163

164

165

independent hospitals, the direction of effect sizes with an external GWAS with a smaller sample size (NIPT PLUS cohort, n = 4,688), and by comparing effect size estimates with publicly available GWAS data for the same phenotypes among general populations, if available. Following the screening process, our analysis included a total of over 85,000 subjects, amalgamating data from the two hospitals (Methods for inclusion and exclusion criteria). Among them, 67,323 participants had available TSH level data within the reference range, and 67,047 participants had available FT4 level data within the reference range. The sample sizes and demographic characteristics of the research subjects included in the GWAS analysis for each trait, such as TSH levels, FT4 levels, TPOAb levels, age, BMI, and gestational weeks at the time of thyroid function measurement, are detailed in **Table S1**. The majority of subjects were in the age range of 29 to 30 years. As expected, maternal serum TSH concentrations decreased from 8 to 12 weeks and then increased in both cohorts, while the opposite changing pattern was observed for FT4 (Figure S1), corresponding to the increase of hCG during pregnancy<sup>[19]</sup>. Genetic associations with normal thyroid function during pregnancy We identified 38 genome-wide significant loci associated with serum TSH levels and Table S2). The genomic inflation factor for the 12,699,587 SNPs was 1.068 for TSH and 1.069 for FT4, suggesting negligible inflation of test statistics in the genome-wide association analysis (Figure S2). Among the 60 loci, 4 TSH loci and 13 FT4 loci were identified as novel, with the lead variant situated more than 500kb away and demonstrated LD R<sup>2</sup> less than 0.1 from any previously established loci (**Table S3**; Figure S3). Among all loci, 59/60(98.3%) loci demonstrated consistent directionality and had a nominally significant P-value below 0.05 between the two hospitals, suggesting little heterogeneity and high fidelity of our genetic discoveries (Table S2, Figure S4A, Figure S4C). The remaining SERPINA7 locus was a known locus associated with FT4 in a previous study and the difference in effect size estimates may be attributed to variations in fetal sex distribution between the two hospitals. In comparison with the GWAS statistics with the NIPT PLUS cohort, 86.7% (52/60) of lead SNPs showed consistent effect directions (Figure S5, Table S2). Given that available genetic studies on thyroid function among East Asians are limited to small sample sizes in the general population (e.g., 3,618 Koreans<sup>[20]</sup>, 4,581 Chinese [21], and 437 Chinese [22]), with only a few suggestive significant sites

- identified for TSH, and the lack of publicly available GWAS summary statistics, we
- 167 compared our effect size estimates with the two largest-scale GWAS studies of TSH
- and FT4 in European populations ( $N_{TSH}=249,715$ ;  $N_{FT4}=49,269$ ) [10,23]. Among the
- loci, 49/60 (81.6%) loci exhibited *P*-values below 0.05 with consistent directional
- effects compared with the European dataset (**Figure S4B**, **Figure S4D**, **Table S2**).
- While the consistent effect size estimates suggest shared genetic determinants
- between the two populations (European and East Asian) and between pregnancy and
- 173 non-pregnancy status, differences in the comparison could be attributed to different
- 174 LD structures between Europeans and East Asians, as indicated by differing allele
- frequencies for the lead SNP (**Figure S6**) or potential effect modifications driven by
- pregnancy status. Further investigation is required to clarify these hypotheses.

#### Novel loci and association signals for TSH and FT4

- The 4 newly identified loci associated with TSH levels comprise *HNRNPA3*, *FGF10*,
- 180 *IGF1*, and *MAGED2* (**Figure 2A, Table S2, Figure S3**). The 13 novel loci associated
- with FT4 levels include SNX7, RRP15, TRH, PDCL2, CAST, CGA, FIG4, UNCX,
- 182 TRHR, ZNF462, GRK5, METTL15, and SGF29 (Figure 2B, Table S2, Figure S3).
- Potential eGenes which expression in 49 issues in GTEx demonstrates colocalization
- signals with the 17 loci are presented in **Table S4**. Among the 17 loci, *HMGA2*, *IGF1*,
- 185 CGA and TRHR contain SNPs that were previously reported to have genome-wide
- associations with several thyroid-related traits in prior GWAS analyses (**Table S3B**).
- And some loci include genes directly involved in thyroid functions, such as TRH and
- 188 TRHR, as well as genes involved in the regulation of protein signal transduction and
- cell proliferation (**Table S5**).

177178

190

198

203

- 191 Furthermore, through stepwise conditional analyses, we identified that 13 out of the
- 192 60 loci contained more than two independent signals, contributing to a total of 33
- independent signals (**Table S6**, **Figure S7**). Particularly, we identified 10 novel
- significant signals within 10 loci known for their involvement in thyroid function
- traits [10 TSH-associated loci: CAPZB, IGFBP5, PDE8B, VEGFA, GLIS3, XPA,
- 196 MBIP, CEP128, DET1, and MAF; 3 FT4-associated loci: GLIS3, FOXE1, and DET1]
- 197 (Table S7, Methods).
- Among the 33 independent signals, the genetic effects of all 33 (100%) SNPs were
- consistent across the two hospitals (**Table S6**), and 26 out of 33 (78.8%) signals
- demonstrated consistent direction and significance at P=0.05 compared to the two
- 202 European datasets mentioned earlier<sup>[10,23]</sup> (**Table S6**).
- 204 Collectively, we identified a total of 53 independent association signals across 38 loci
- for TSH levels and 27 signals across 22 loci for the FT4 levels, collectively
- explaining 6.6% and 2.8% of the phenotypic variance, respectively.

208 Genetic associations with normal thyroid function within 8-12 gestational weeks 209 Considering the strong stimulation of thyroid function by hCG, leading to a 210 significant reduction in TSH and an increase in FT4 during early pregnancy (weeks 8 211 to 12, Figure S1), we conducted a more focused GWAS analysis within this specific 212 timeframe (weeks 8 to 12) to investigate potential association loci related to hCG 213 stimulation. Within the 8 to 12 weeks period, we identified 20 genome-wide 214 significant loci associated with TSH levels and 11 loci associated with FT4 levels 215 (**Figure S8**). However, after applying the Bonferroni correction, we did not find any 216 loci associated with TSH/FT4 within 8 to 12 weeks that were related to previously published hCG GWAS after Bonferroni correction (**Table S8**)<sup>[24]</sup>. These findings 217 218 suggest that the gestational TSH and FT4 level do not share a significant genetic 219 correlation with hCG. 220 221 Interestingly, when comparing the genetic effects of the 31 loci within the 8 to 12 222 weeks period with the effects estimated from the entire pregnancy period, we 223 observed that the effect size for 4 out of the 20 TSH loci and 6 out of the 11 FT4 loci 224 did not have overlapping 95% confidence intervals between the two periods (Figure 225 **S9 and Table S9).** Notably, the TSH receptor locus (*TSHR*, marked by the nearest 226 gene CEP128) showed stronger associations with TSH and FT4 specifically during 227 the 8 to 12 weeks timeframe of pregnancy. According to GTEx, we found that the 228 lead SNP mutation rs17111346-G, associated with TSH levels during the 8-12 229 gestational weeks, was associated with a higher TSHR expression level in several 230 tissues and organs (Figure S10). In our study, this variant was associated with 231 increased TSH levels and reduced FT4 levels (**Table S9**). These observations may 232 provide a genetic explanation for the occurrence of hypothyroxinemia during this 233 stage, despite hCG stimulation. Individuals carrying specific genetic variants, 234 unrelated to hCG stimulation but associated with lower FT4 and higher TSH during 235 early pregnancy, such as the rs17111346-G variant, may have a higher risk of 236 developing hypothyroxinemia, despite hCG stimulation. 237 238 239 Identification of genetic associations with thyroid dysfunction 240 During early pregnancy, the fetus heavily relies on maternal thyroid hormones. 241 Evidence underscores the correlation between untreated clinical thyroid dysfunction and adverse birth outcomes<sup>[25,26]</sup>. Subclinical hypothyroidism, characterized by low 242 243 TSH levels but normal FT4 level, and isolated hypothyroxinaemia, characterized by 244 low free T4 levels and normal TSH levels—represent common mild thyroid 245 dysfunctions during pregnancy associated with adverse pediatric outcomes, including preterm birth<sup>[4]</sup>. Nevertheless, the optimal management of subclinical thyroid 246 247 dysfunction remains contentious, as some treatments for subclinical hypothyroidism 248 or hypothyroxinemia have not significantly improved cognitive or birth

outcomes<sup>[26,27]</sup>. Moreover, untreated overt hyperthyroidism during pregnancy is linked to various maternal and fetal complications, such as pre-eclampsia and pregnancy loss.

to various maternal and fetal complications, such as pre-eclampsia and pregnancy loss, while subclinical hyperthyroidism is not thought to be associated with adverse birth

252 outcomes<sup>[28]</sup>.

251

253

272

- 254 To elucidate the genetic underpinnings of these thyroid dysfunctions, we conducted a
- 255 GWAS analysis on four categorical traits: subclinical hypothyroidism, isolated
- 256 hypothyroxinemia, overt hyperthyroidism, and subclinical hyperthyroidism (cases).
- We utilized pregnant women with euthyroid function, defined as those maintaining
- 258 TSH and FT4 levels within the pregnancy-specific reference range throughout
- pregnancy, as the control group. Notably, we also examined clinical hypothyroidism;
- 260 however, the statistical power was limited due to the small number of cases
- 261 (N<sub>Longgang</sub>=464, N<sub>Baoan</sub>=148) and robust genetic associations were not identified.
- Specifically, we excluded individuals who tested positive for TPOAb from both the
- 263 case and control populations in the analysis for isolated hypothyroxinemia. After
- 264 exclusions, the sample sizes of the included research subjects were as follows: (1)
- subclinical hypothyroidism [N=73,050 (Longgang: 3,666 cases versus 43,525 controls;
- 266 Longang: 1,244 cases versus 24,615 controls)]; (2) isolated hypothyroxinemia:
- 267 [N=50,407 (Longgang: 2,981 cases versus 37,152 controls; Longang: 613 cases
- versus 9,961 controls)]; (3) subclinical hyperthyroidism [N=72,631(Longgang: 2,598
- cases versus 43,525 controls; Longang: 1,893 cases versus 24,615 controls)]; (4)
- overt hyperthyroidism [N=69,788 (Longgang: 1,229 cases versus 43,525 controls;
- 271 Longang: 419 cases versus 24,615 controls)].
- Our analysis led to the identification of 18, 8, 12, and 7 genome-wide association loci
- associated with maternal subclinical hypothyroidism, isolated hypothyroxinemia,
- subclinical hyperthyroidism, and overt hyperthyroidism, respectively (**Figure 3**,
- Table S10, Figure S11). eGenes with colocalization signals with these 45 loci are
- presented in **Table S4**. All lead SNPs in these 45 loci exhibited consistent
- directionality within two hospitals, with 42 out of 45 (93.3%) compared at a *P-value*
- below 0.05 with consistent directionality (Figure S12A). When we replicated these
- 45 lead SNPs with the NIPT PLUS cohort, 77.8% (35/45) SNPs showed consistent
- directions of genetic effects (**Figure S12B**).
- 283 As no previous GWAS studies have been conducted on the four thyroid dysfunctions
- investigated in this study, we were unable to directly compare the outcome with
- 285 external datasets. However, we noted that most of these loci have been reported to be
- associated with thyroid-related traits such as hypothyroidism, TSH, and FT4 (**Table**
- 287 **S3B**). After excluding loci previously associated with thyroid traits, we identified 2
- 288 novel low-frequency genome-wide thyroid-traits loci including isolated
- 289 hypothyroxinemia-related *SPRYI* (rs190595112-G, MAF=0.012, OR[95%]:4.22[2.52-
- 290 7.07], P= 4.77E-08) and overt hyperthyroidism-related *GAPVD1* (rs78254323-T,

- 291 MAF=0.04, OR[95%]: 1.72[1.42-2.09], P= 3.94E-08). These two variants
- demonstrated consistent directionality and significance between the two hospital
- 293 cohorts (**Table S10**). The *GAPVD1* locus demonstrated certain levels of evidence of
- associations with GAPVD1 expression in the thyroid, while we did not find eGene for
- 295 SRYI locus in all tissues (**Table S4**).

### Genetic associations with thyroid autoimmunity

- 298 Thyroid autoimmunity, characterized by the presence of antibodies targeting
- 299 thyroperoxidase, thyroglobulin, and thyroid-stimulating hormone receptor antibodies
- 300 (TRAbs), is prevalent among pregnant women and is often diagnosed through the
- detection of thyroperoxidase antibodies (TPOAb) in clinical settings. This condition
- is associated with thyroid dysfunction and adverse obstetric outcomes<sup>[29]</sup>. In this study,
- 303 we conducted genome-wide association studies (GWAS) focusing on TPOAb
- quantitative levels and positivity during pregnancy (Methods). The sample sizes of
- the included research subjects were as follows (1) quantitative TPOAb levels [N=
- 306 60,225 (Longgang: 46,023; Longang: 14,202)]; (2) TPOAb-positivity [N=
- 307 69,061(Longgang: 7,324 cases versus 45,542 controls; Longang: 2,894 cases versus
- 308 13,301 controls)].

296297

309

- We identified 38 and 33 loci associated with TPOAb levels and TPOAb positivity,
- respectively (**Figure 4, Figure S13 and Table S11**), revealing 35 and 30 newly
- 312 identified association loci, respectively compared to previously reported signals in the
- 313 GWAS catalog. Most of the loci for both traits were shared. The four most significant
- 314 novel loci including VANGL2, CTLA4, GPX6, and GPR174, were identified as
- associated with Graves' disease (GD)/Hashimoto's thyroiditis (HT) in the Japanese
- population<sup>[30]</sup> (**Table S3B**). We identified 4 missense variants in novel loci:
- 317 rs7522061-C in FCRL3, rs3775291-T in TLR3, rs12793348-G in PANX1 and
- 318 rs229527-C in C10TNF6. GWAS-eQTL co-localization analyses identified several
- 319 TPOAb levels and positivity-related loci that regulate the expression of *RPS26*,
- 320 RNASET2, C10TNF6, FCRL1, FCRL3 genes in multiple tissues (**Table S4**). Previous
- 321 study has reported that RNASET2 is expressed in CD4 + T-helper and CD8 + T
- cells<sup>[31]</sup>, while *FCRL3* is expressed at high levels during the maturation of B-cells and
- is thought to regulate B-cell signaling in both positive and negative ways<sup>[32]</sup>. FCRL1
- also plays a role in the assembly of the BCR signalosome, influences B cell signaling,
- and enhances humoral responses<sup>[33]</sup>.
- For consistency, 67 out of 71 (94.4%) loci demonstrated consistent direction and
- significance at P=0.05 between the two hospitals (**Figure S14A, Table S11**). When
- 329 replicating GWAS for TPOAb levels and positivity in the NIPT PLUS cohort, 62 out
- of 71 (87.3%) loci showed consistent directions of genetic effects (**Figure S14B**,
- Table S11). Comparing the results with external datasets, we initially compared our
- results with the largest previous GWAS study on TPOAb levels and positivity,

conducted by Marco Medici et al. in the European population in 2014 (N<sub>TPOAb</sub>-

- <sub>levels</sub>=16,528 and N<sub>TPOAb-positivity</sub>=18,297)<sup>[34]</sup>. Since the study involved 2.14 million
- variants, only 58 of our lead variants (for their proxy SNPs) were available for
- analysis in this study. Among these SNPs, 50 loci (86.2%) exhibited a consistent
- direction of effect between Chinese pregnant women and the European population
- 338 (**Figure S15, Table S12**).

334

339

353354

364

- 340 Given the unavailability of previous GWAS summary data for TPOAb in the East
- 341 Asian population and the high correlation between TPOAb positivity and autoimmune
- thyroid diseases such as Graves' disease and Hashimoto's thyroiditis<sup>[35]</sup>, we also
- examined our associations for TPOAb positivity using the GWAS results for Graves'
- disease and Hashimoto's thyroiditis from the Biobank Japan (BBJ)<sup>[30]</sup>. Of these 33 loci,
- 345 *H2BC8* (rs1051365311) and its proxy SNP were not available in the BBJ dataset.
- 346 According to the result, 15 loci (FCRL3, VANGL2, CTLA4, LPP, CLNK, TCF7, IRF4,
- 347 GPX6, HBS1L, RNASET2, FAM76B, IFT81, MAF, C1QTNF6, and GPR174) in
- Grave's disease (**Table S13, Figure S16A**) and 2 loci (*GPX6, VANGL2*) in
- 349 Hashimoto's thyroiditis showed significant associations (**Table S13, Figure S16B**).
- 350 The high degree of concordance (32 out of 33) in the direction of locus effects
- 351 suggests a shared genetic basis between TPOAb positivity during pregnancy and
- autoimmune thyroid diseases.

## Pairwise genetic correlation among thyroid traits

- 355 To explore the pairwise genetic correlation among the thyroid traits investigated, we
- employed LD score regression<sup>[36]</sup>. The analysis revealed a significant genetic
- 357 correlation between TSH and all other thyroid traits, including TPOAb levels and
- positivity. Conversely, FT4 exhibited correlation with thyroid dysfunctions but not
- with TPOAb levels and positivity (Figure S17, Table S14). Additionally, we
- 360 observed a correlation between TPOAb level/positivity and subclinical
- 361 hypothyroidism. Nonetheless, this genetic correlation lost significance when the
- analysis was restricted to euthyroid individuals, suggesting that the observed
- 363 correlation stemmed from shared genetics between TPOAb and TSH.
- Consistent with the established inverse correlation in TSH and FT4 regulation through
- the Hypothalamus-Pituitary-Thyroid Axis (HPT) [37], we observed a significant
- inverse genetic correlation between TSH and FT4 levels (the genetic correlation
- 368 calculated by LDSC: rg<sub>TSH-FT4</sub>=-0.16, se=0.04, P=8.6E-5)(**Figure S17, Table S14**),
- along with shared associations at 11 loci (TSH: CAPZB, TNS1, GLIS3, XPA, MBIP,
- 370 DET1, MAF, and FT4: FIG4, GLIS3, FOXE1, DET1) (Bonferroni-corrected threshold
- 371  $p \square < \square 0.05/60$ ) (**Figure S18, Table S15**). At these 11 loci, alleles associated with
- 372 higher TSH levels were consistently associated with lower FT4 except for three loci -
- 373 FIG4, XPA, and FOXE1 where genetic effects were observed in the same direction
- for both thyroid-related hormones.

377

378

379

380

381

382

383 384

385 386

387 388

389

390391392

393

394

395

396

397

398

399

400

401 402

403

404

405

406

407

408

409

410

411

412413

414

415

416

The influence of thyroid-related traits on gestational complications and fetal obstetric outcomes Previous large meta-analyses of observational studies have demonstrated an association between subclinical thyroid dysfunction and maternal complications and adverse birth outcomes, including gestational diabetes mellitus (GDM)<sup>[38]</sup>, hypertensive disorders<sup>[39]</sup>, miscarriage <sup>[40]</sup>, preterm birth, and low birth weight<sup>[4,5]</sup>. However, RCTs investigating treatments for mild thyroid function abnormalities have yielded inconclusive results <sup>[27]</sup>, resulting in uncertainty and controversy regarding the relationship between subclinical dysfunction and pregnancy outcomes, as well as the therapeutic value of addressing mild abnormalities<sup>[41,42]</sup>. High-quality Mendelian randomization studies in clinical thyroidology are deemed crucial for gaining valuable insights into the relationship between thyroid functions and birth outcomes<sup>[43]</sup>. However, to date, only one MR study has explored the causal effect of TSH and FT4 levels within the normal range on birth weight and did not identify statistically significant causal associations [44]. Here, we applied joint phenotypic association and Mendelian randomization to investigate the impact of thyroid function during pregnancy on gestational complications such as hypertension, and gestational diabetes, as well as birth outcomes including birth weight, birth length, and gestational duration (**Table S18**). Adhering to the three preconditions for a robust MR analysis, we utilize strong instrumental variables (F > 10), accounted for heterogeneity and horizontal pleiotropy by applying an inverse weighted approach of random effect (IVWRE) as primary results, and conducted several sensitivity analyses, including six additional two-sample MR approaches and three scenarios including overlapping (Meta-Meta) and non-overlapping samples (Longgang-Bao and Baoan-Longgang)<sup>[45]</sup>. In addition, for MR analysis of the relationship between thyroid traits and pregnancy complications, we accounted for the bi-directionality of the causal estimates (**Method**). Notably, due to the extreme imbalance in the number of cases and controls of gestational hypertension and preeclampsia, we employed quantitative systolic and diastolic blood pressure as indicators for hypertension. Considering the substantial genetic correlation among the gestational thyroid traits (Figure S17), we employed a Bonferroni testing criteria based on the total number of investigated gestational complication and fetal obstetric outcomes (N=14). The statistical results of all methods are presented in **Table S18 and S20**, while the instrumental variables used are listed in **Table S19**. Phenotypic association tests revealed numerous strong associations between TSH and FT4 within the normal range, thyroid dysfunction, and glucose and blood pressure traits, including significant associations between ISH and GDM (P < 0.004) (Figure **5A, Table S17**). Mendelian randomization suggested consistent potential causal

417 associations for a few of these correlations after Bonferroni correction, including a 418 significant negative effect of TSH on fasting plasma glucose (FPG), oral glucose 419 tolerance at 1 hour (OGTT1H), and systolic blood pressure (SBP), as well as a 420 significant effect of FT4, SHO, SHP on SBP (**Figure 5B-C, Table S18,** P < 0.004). 421 Additionally, we found a nominally significant protective effect of genetically 422 increased thyroid hormone (FT4) on GDM, consistent between MR and observational 423 studies (observational study: OR<sub>longgang</sub> [95%CI]: 0.861[0.833~0.89], P<sub>longgang</sub> =8.49E-424 19; MR: OR[95%CI]:0.844[0.732~0.972], P=1.88E-02). Reverse Mendelian 425 randomization did not identify significant potential causal associations between the 426 pregnancy phenotypes and thyroid-related phenotypes after Bonferroni correction 427 (Figure 5B, Table S20). 428 429 As for birth outcomes, observational analysis in the Longgang and Baoan study 430 consistently showed that maternal FT4 levels within the reference range were 431 significantly associated with lower birth weight, shorter birth length and a higher risk 432 of low birth weight. Correspondingly, we also observed a consistently significant 433 positive correlation between isolated hypothyroxinemia during pregnancy and greater 434 birth weight, as well as a significant association between TPOAb levels and 435 decreasing birth weight (Figure 6A, Table S17). However, in MR analysis, we only 436 discovered a significant potential causal effect of elevated TSH levels during 437 pregnancy on greater gestational duration (days) after Bonferroni correction ( $\beta_{MR}$ 438 IVWRE 95%CI =0.07[0.04-0.11], P<sub>MR-IVWRE</sub>=7.80E-5) (**Figure 6B, Table S18**). Similar 439 results were observed across other methods of Mendelian randomization, except for 440 simple mode (SM), which showed attenuation toward the null. We did not identify 441 MR associations between thyroid dysfunction and birth outcomes (Figure 6B, Table 442 **S18**). 443 444 Bidirectional Mendelian randomization study between gestational thyroid traits 445 and 220 phenotypes in BioBank Japan 446 We further investigated the potential relationship between thyroid-related traits during 447 pregnancy and 220 health phenotypes and outcomes in Biobank Japan (BBJ), with an 448 average age of 62, by conducting a bidirectional Mendelian randomization analysis 449 (Methods). Consistent significant associations in both directions suggest genetic 450 sharing rather than causal relation. The Bonferroni testing criteria are based on the 451 total number of investigated BBJ phenotypes (N=220), considering the substantial 452 genetic correlation among the gestational thyroid traits (Figure S17). Results 453 surpassing the Bonferroni and MR Egger pleiotropy testing criteria, which mainly 454 pertain to BBJ thyroid and cardiac disorders, are discussed herein. The instrumental 455 variables used in the forward MR analysis are presented in **Table S22**. 456 457 Regarding thyroid autoimmunity, forward MR analysis suggested that genetically 458 determined elevated susceptibility to TPOAb positivity is associated with an increased

- risk for all 7 thyroid disorders, with 6 of these associations remaining significant after
- 460 Bonferroni correction: Graves' disease (OR [95%CI]:1.55[1.41~1.704], P=9.68E-20),
- 461 thyroid preparations usage (1.364[1.259~1.478], P=2.66E-14), hypothyroidism
- 462 (1.441[1.297~1.6], P=9.10E-12), hyperthyroidism(1.478[1.318~1.658], P=2.37E-11),
- 463 Hashimoto thyroiditis(1.454[1.27~1.666], P=6.61E-08), and goiter
- 464 (1.163[1.077~1.256], P=1.12E-04) (**Figure 7, Figure S19A~F, Table S21**). Similar
- observations apply to TPOAb levels and for euthyroid TPOAb positivity with normal
- 466 TSH and FT4 levels (Figure S19G~N). However, in the reverse MR, statistics are
- unavailable for thyroid cancer, hypothyroidism, Hashimoto thyroiditis and goiter due
- 468 to unavailability of instrumental variables. Significant bidirectionality was observed
- 469 for Graves' disease and thyroid preparations, and same effect direction was observed
- 470 for hyperthyroidism (**Figure 7**). Therefore, we infer that TPOAb positivity and levels
- during pregnancy are genetically correlated with the BBJ thyroid disorders. In
- 472 addition to thyroid-related diseases, forward MR also revealed that genetic TPOAb
- positivity is associated with a reduced risk of depression (OR [95%CI]:
- 474 OR[95%CI]:0.848[0.793~0.907], P=1.60E-06) and an increased risk of Cardiac
- 475 valvular disease (OR [95%CI]: OR[95%CI]:1.109[1.052~1.169], P=1.24E-04)
- 476 (Figure S190~P). Reverse MR is unavailable for both disorders due to a lack of IVs
- 477 (**Figure 7, Table S23**).

493

494

- In the forward MR analysis of both normal TSH, FT4 and thyroid dysfunction, we
- observed that genetically elevated TSH levels, and a high risk of subclinical
- 481 hypothyroidism were linked to an increased usage of thyroid preparations, while overt
- 482 hyperthyroidism was linked to a decreased usage of thyroid preparations (P < 1.72E-
- 483 04) (Figure 7, Figure S20A~C and Table S21). Except for overt hyperthyroidism,
- 484 TSH and subclinical hypothyroidism suggest bi-directionality of the MR effect. In
- 485 addition, genetically elevated TSH (OR [95%CI]:0.66[0.55-0.79], P=1.12E-05) and
- 486 subclinical hypothyroidism (OR[95%CI]:0.81[0.74-0.89], P=8.54E-06) were
- associated with a lower risk of goiter (**Figure S20D-E**). However, reverse MR is
- unavailable for both disorders due to a lack of IVs (**Figure 7, Table S23**). Moreover,
- 489 we found genetically elevated TSH levels but not thyroid dysfunction are associated
- 490 with a reduced risk of atrial fibrillation (OR [95%CI]: 0.868[0.81~0.931], P=7.91E-05)
- 491 (Figure S20F), which did not demonstrate evidence of causality in the reverse MR,
- 492 suggesting potential causal relation.

# Discussion

- 495 Utilizing hospital electronic medical records and NIPT data from 85,421 Chinese
- 496 pregnancies, we conducted the first and most comprehensive GWAS studies to date of
- 497 thyroid traits during pregnancy, encompassing thyroid-related hormones, dysfunction,
- 498 and autoimmunity. Simultaneously, our GWAS facilitates the exploration of thyroid

500

501502

503

504

505

506

507

508

509510

511

512

513

514

515

516

517518

519

520

521

522

523

524

525

526527

528

529

530

531

532

533

534

535

536

537

538

539540

function's impact on gestational complications as well as on birth outcomes, utilizing the methods of Mendelian randomization. In summary, we identified 176 genome-wide loci, among which 125 genome-wide associations had not been previously reported for the 8 thyroid-related traits. This significantly enhances our understanding of the genetic basis of thyroid traits during pregnancy. The high consistency of genetic effects observed across two independent hospitals, and in comparison with external datasets demonstrates the robustness of our GWAS results. Particularly, while the TRH and TRHR genes are well-established in the thyroid axis<sup>[37]</sup>, our study is the first to identify them as genome-wide association loci for thyroid function (FT4), signifying a significant power gain in our analysis. Moreover, we identified 33 independent association signals in 13 loci (TSH: CAPZB, IGFBP5, PDE8B, VEGFA, GLIS3, XPA, MBIP, CEP128, DET1, and MAF; FT4: GLIS3, FOXE1, and DET1) by the stepwise conditional analysis, suggesting allelic heterogeneity at the thyroid-associated loci. Additionally, comparing the genetic associations with normal TSH and FT4 within 8-12 gestations suggests that individuals carrying specific genetic variants have a higher risk of hypothyroxinemia, despite hCG stimulation. In the first GWAS of gestational thyroid dysfunction, we identified 18, 8, 12 and 7 genome-wide loci associated with subclinical hypothyroidism, isolated hypothyroxinemia, and subclinical hyperthyroidism, and overt hyperthyroidism during pregnancy, respectively. Additionally, our study has doubled the number of genome-wide loci associated with TPOAb levels and positivity. These loci also exhibited connections with other thyroid-related traits and conditions, including hypothyroidism, TSH levels, and the use of thyroid preparations. Further functional and mechanistic studies may be warranted to explore potential new therapeutic targets. We completed the first joint epidemiological and Mendelian randomization analysis of gestational thyroid phenotypes and complications. Statistics suggest that genetically predicted lower TSH and higher FT4 correlate with elevated blood glucose levels. However, we did not identify a significant MR association between thyroid dysfunction and GDM, implying a continuum of TSH and FT4 action on blood glucose and blood pressure regulation. Previous studies have yielded conflicting conclusions regarding the association between subclinical hypothyroidism and GDM<sup>[46-48]</sup>, and our results suggest that the impact of abnormal thyroid function on GDM varies depending on the criteria used for TSH and blood glucose assessment. Moreover, our results suggest the involvement of TSH and FT4 in blood pressure regulation. While a previous MR analysis suggested that genetically predicted TSH elevation leads to reduced systolic blood pressure, this finding lacked significance after Bonferroni correction [49]. Our study provides more robust evidence to support this conclusion.

543

544

545

546547

548

549

550

551

552

553

554

555

556

557

558559

560561

562

563

564

565

566567

568

569

570

571

572573

574

575

576

577

578579

580

581

582

In the investigation of relationship of gestational thyroid phenotypes and birth outcomes, retrospective observational analyses revealed that isolated hypothyroxinemia was associated with higher birth weight, while FT4 levels within the reference range were inversely associated with birth weight, aligning with findings from a previous large meta-analysis<sup>[5]</sup>. However, we did not find sufficient evidence to suggest that abnormal TSH levels during pregnancy (overt and subclinical hyperthyroidism, subclinical hypothyroidism) and TPOAb positivity increase the risk of adverse outcomes such as preterm delivery, macrosomia, and low birth weights. Nonetheless, we cannot exclude the possibility that thyroid dysfunction and autoimmunity may contribute to other adverse outcomes. Consistent with a previous MR study<sup>[44]</sup>, we also did not identify an MR association between maternal TSH levels within the reference range and birth weight. Notably, our MR analyses provide evidence suggesting that maternal TSH levels during pregnancy may potentially influence gestational duration, although the effect may be nonlinear. Notably, genetically predicted higher maternal TSH are nominally associated with a heightened risk of preterm birth, and previous research has demonstrated a U-shaped association between FT4 levels and preterm birth<sup>[50]</sup>. Further validation through intervention studies is warranted to ascertain the genuine effects. TPOAb is commonly acknowledged as a pathogenic antibody associated with Hashimoto's thyroiditis (HT), yet its role in Graves' disease (GD) remains uncertain, despite the fact that 50-70% of individuals with GD also exhibit TPOAb positivity<sup>[51,52]</sup>. TPOAb has been proposed as a marker of impaired thyroid function rather than a direct cause of thyroid damage<sup>[2]</sup>. Our bidirectional MR analyses with BBJ phenotypes suggest a genetic correlation between TPOAb positivity and several thyroid disorders in older, general individuals, regardless of their thyroid function status. Additionally, we observed that genetically predicted maternal TPOAb positivity was associated with an increased risk of cardiac valvular disease, consistent with previous observations of an association between thyroid autoimmunity and rheumatic heart valve disease<sup>[53]</sup>. In addition, in line with the findings of previous MR studies conducted in population of European ancestry<sup>[23,54]</sup>, identified protective effects of lower thyroid function during pregnancy against atrial fibrillation and goiter in East Asians. The consistently observed genetic correlation or MR associations of gestational thyroid phenotypes and later-age thyroid and cardiac diseases suggest the potential for early screening of thyroid disorders in early adulthood and may warrant further clinical studies. Despite the positive findings, there are limitations in our study. Firstly, while we conducted the first and most comprehensive GWAS study of thyroid-related traits in pregnancy, focusing on a critical period of human reproduction, the study population consisted solely of Chinese women, potentially limiting the generalizability of our

584

585

586 587

588

589

590

591592

593

594

595

596 597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615616

617

618

619

620 621

622

623

624

findings to other ancestries. However, we would like to note that non-invasive prenatal testing data are widely adopted in clinical settings due to their high sensitivity and specificity<sup>[55]</sup>. The methods used in this study<sup>[17,18]</sup> will facilitate further investigations into thyroid-related traits in pregnancy across different populations, enhancing our understanding of the trans-ancestral genetic basis. In addition, the shared genetic correlation between the gestational thyroid traits in this study and the thyroid phenotypes in European general population suggests that the existance of strong correlation between thyroid traits in different life stages. Secondly, in our Mendelian randomization analysis examining the relationship between gestational thyroid traits and complications as well as birth outcomes, we utilized a strategy involving two-sample MR analytical methods within a single cohort setting, which has been empirically proved not to be prone to sampleoverlapping bias if the IVs were sufficiently strong<sup>[45]</sup>. Nonetheless, to enhance the robustness of our findings, replication in a two-sample MR without sample overlap would be ideal. We attempted to address this by conducting analyses in multiple scenarios, including using exposures from one hospital and outcomes from the other hospitals, to support our MR results. These strategies consistently suggested that genetically determined elevated TSH levels during pregnancy were associated with lower glycemic levels, reduced blood pressure, and longer gestational duration. Furthermore, in our MR study of gestational thyroid traits and birth outcomes, we did not differentiate between fetal genetic and intrauterine effects of exposure on birth outcomes. This aspect could benefit from expansion of sample size in family genomes from birth cohorts in Chinese ancestry<sup>[56]</sup>. Additionally, when analyzing the impact of thyroid traits on other outcomes, we focused solely on additive linear effects, without considering nonlinear effects. Finally, in the bidirectional MR study between gestational thyroid traits and phenotypes in BBJ, we were unable to distinguish genetic correlation from potential causal effect of the exposures of thyroid related traits during pregnancy on a later-age health result. This purpose can be addressed when GWAS studies of the same thyroid traits investigated in this study among general East Asian population become available, enabling a multi-variable Mendelian randomization analysis integrating GWAS statistics of thyroid traits in pregnancy and among the general populations<sup>[57]</sup>. Despite the genetic findings, our study suggests two clinical implications. First, serum levels of TSH and FT4 exhibit substantial interindividual variation among healthy individuals, with much smaller intraindividual variation<sup>[58]</sup>. This indicates that each person has a unique setpoint for TSH and FT4<sup>[59]</sup>. Hence, when initiating RCTs or treatments for thyroid disorders in pregnant women, it may be beneficial to consider the genomic profile of the patients, as revealed in our study. This approach can help prevent overtreatment, may explain the varying responses of the pregnant women to medications such as levothyroxine, commonly prescribed for gestational thyroid

disorders<sup>[27]</sup>. Secondly, as pregnancy screening represents the most comprehensive physical examination during early adulthood for most women, it is valuable to explore early diagnosis and preventive strategies for thyroid disorders later in life, starting from this critical early period.

**Methods** 630 Longgang and Baoan Study 631 632 The Longgang Study enrolled 70,608 pregnant women who received NIPT results 633 during the first or second trimester at Longgang District Maternal and Child Health 634 Hospital, located in the eastern region of Shenzhen, China, between 2017 and 2022. 635 Of these, 58,351 participants had available measurements for TSH, FT4, and TPOAb 636 levels. 637 638 The Baoan Study included 50,948 pregnant women who visited the Baoan District 639 Maternal and Child Health Hospital in the western region of Shenzhen, China, and 640 completed an NIPT test during the first or second trimester between 2017 and 2022. 641 Of these, 33,781 participants had available TSH measurements, 33,516 had FT4 642 measurements, and 16,393 had TPOAb measurements. 643 644 This study was reviewed and approved by the Ethics Committee of School of Public 645 Health (Shenzhen), Sun Yat-Sen University (2021. No.8), as well as the Institutional 646 Board of Shenzhen Baoan Women's and Children's Hospital (LLSC2021-04-01-10-647 KS) and Longgang District Maternity and Child Healthcare Hospital of Shenzhen 648 City (LGFYYXLLL-2022-024). The study strictly adhered to regulations governing 649 ethical considerations and personal data protection. Data collection was approved by 650 the Human Genetic Resources Administration of China (HGRAC). Written informed 651 consent of all participants were obtained. 652 653 Biochemical measurements and definition of thyroid-related traits Because TSH and FT4 concentrations during pregnancy are related to gestational 654 week, pregnancy-specific reference ranges are recommended<sup>[1]</sup>. In this project, the 655 656 diagnosis of thyroid dysfunction was based on a method-specific and pregnancy-657 specific reference interval, as recommended by the Chinese Medical Association Guideline on the diagnosis and management of thyroid diseases during pregnancy and 658 postpartum (2nd edition)<sup>[60]</sup>. We also used the cutoff value provided by the kit 659 company to determine whether the subject was in a TPOAb positivity state. 660 661 662 In the Longgang study, thyroid function tests measured concentrations of thyroid 663 stimulating hormone (TSH), free thyroxine (FT4), and anti-thyroid peroxidase 664 antibody (TPOAb). These measurements were taken during a physical examination 665 using the UniCel DxI 800 Immunoassay System (Beckman Coulter Inc., Brea, CA, 666 USA) along with its respective system accessory kit. The reference ranges for TSH 667 are 0.05-3.55 mIU/L for the first trimester, 0.21-3.31 mIU/L for the second trimester, 668 and 0.43-3.71 mIU/L for the third trimester. The reference ranges for FT4 are 9.01-669 15.89 pmol/L for the first trimester, 6.62-13.51 pmol/L for the second trimester, and

6.42-10.75 pmol/L for the third trimester<sup>[60]</sup>. TPOAb positivity was defined according 670 671 to the cutoff (TPOAb > 9 IU/mL). 672 673 In Baoan study, serum levels of TSH, FT4, and TPOAb were measured by Abott 674 I2000 Immunoassay System. The reference ranges of TSH are (0.07-3.38 mIU/L), 675 (0.34-3.51 mIU/L) and (0.34-4.32 mIU/L) for the first trimester, second trimester and 676 third trimester, respectively. And the reference ranges of FT4 are (11.30-17.80 677 pmol/L), (9.30-15.20 pmol/L) and (7.90-14.10 pmol/L) for the first trimester, second trimester, and third trimester, respectively<sup>[60]</sup>. The cut-off value we used for TPOAb 678 679 positivity is 5.6 IU/ml. 680 681 In each study, a pregnant woman with both TSH and FT4 levels within the 682 pregnancy-specific reference range was considered a subject with normal thyroid 683 function (ie, euthyroidism). The serum TSH and FT4 levels were analyzed as 684 continuous variables after inverse normal transformation, based on the euthyroid 685 subjects. Additionally, for the GWAS of continuous TPOAb levels, pregnant women 686 exhibiting TPOAb levels below the minimum detection limits of the assay (0.25) 687 IU/ml for the Longgang Study and 0.159 IU/ml for the Baoan Study) were excluded. 688 TPOAb levels were natural log-transformed before performing the GWAS analysis. 689 690 The thyroid dysfunction was defined following the 2017 medical guidelines of the 691 American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum<sup>[1]</sup>. Specifically, overt hyperthyroidism was 692 693 defined as a TSH concentration below the lower limit of the reference range, 694 accompanied by an FT4 concentration exceeding the upper limit of the reference 695 range. Subclinical hyperthyroidism was defined as a TSH concentration below the 696 lower limit of the reference range while maintaining a normal FT4 concentration. 697 Subclinical hypothyroidism was defined by as a TSH concentration upper the limit of 698 the reference range with normal FT4 concentration. Isolated hypothyroxinemia is 699 typically defined as having an FT4 concentration below the lower limit of the 700 reference range while maintaining a normal maternal TSH concentration. 701 702 To comprehend the genetic underpinnings of these thyroid dysfunctions, we 703 conducted a GWAS analysis on four categorical traits: subclinical hypothyroidism, 704 isolated hypothyroxinemia, overt hyperthyroidism, and subclinical hyperthyroidism 705 (case group). We used pregnant women with euthyroid function, defined as those 706 maintaining TSH and FT4 levels within the pregnancy-specific reference range 707 throughout pregnancy, as the control group. Specifically, we excluded individuals 708 who tested positive for TPOAb from both the case and control populations in the 709 analysis for isolated hypothyroxinemia (**Table S1**). It is worth noting that we also 710 examined overt hypothyroidism; however, the statistical power was limited due to the

711 small number of cases (N<sub>Longgang</sub>=464, N<sub>Baoan</sub>=148) and we did not identify robust 712 genetic associations. 713 714 **Statistical analysis** 715 For all participants, baseline characteristics were described using mean  $\pm$  standard 716 deviation, and results of thyroid function tests (TSH, FT4, and TPOAb) for different 717 pregnancies were presented in median [interquartile range]. In the phenotype 718 association analysis of thyroid-related traits with gestational complications and fetal 719 obstetric outcomes, quantitative traits were analyzed using multiple linear regression, 720 and categorical traits were analyzed using logistic regression. All statistical analyses 721 were conducted using R version 4.3.2. 722 723 Genotyping, Imputation, and Variant annotation 724 Non-invasive prenatal testing (NIPT), which employs low-pass massively parallel 725 sequencing of cell-free DNA fragments from peripheral blood of a pregnant woman, 726 has gained prominence as an unparalleled screening test for fetal aneuploidy due to its high sensitivity and specificity<sup>[61]</sup>. Our prior research and recent study have illustrated 727 that when NIPT data (0.06x - 0.3x) are integrated with a reference panel, it can 728 729 achieve high accuracy in genotype imputation, matching or even exceeding the performance of an array<sup>[17,18]</sup>. 730 731 732 In summary, we first collected data from NIPT for 121,578 pregnant women in Baoan 733 and Longgang Hospitals in Shenzhen city, Guangdong Province. Each of these 734 participants was whole-genome sequenced to 9.9-21.9 million cleaned reads, representing a sequencing depth of around 0.11x-0.25x. Next, we applied BWA<sup>[62]</sup> to 735 736 align the cleaned reads to the Genome Reference Consortium Human Reference 38 (GRCh38) and used the rmdup option in samtools<sup>[63]</sup> to remove potential PCR 737 duplicates. The GATK realignment and base quality recalibration method was utilized 738 to align the reads and adjust base quality scores<sup>[64]</sup>. After that, the alignment files were 739 740 stored as bam files. 741 742 Subsequently, we employed the Glimpse software (version 1.1.1)<sup>[65]</sup>, which 743 implements an algorithm for genotype imputation, in conjunction with a deep wholegenome sequencing reference panel of 10K Chinese<sup>[66]</sup>, to perform individual 744 745 genotype imputation for the NIPT data. Finally, variant annotation was carried out using Ensembl Variant Effect Predictor<sup>[67]</sup> (version 101), utilizing indexed GRCh38 746 747 cache files (version 109). All the data used for annotation were obtained in advance 748 from the Ensembl FTP server (https://ftp.ensembl.org/pub/). Considering that a 749 variant can span across multiple transcripts, we employed the "--pick" option to 750 assign a single consequence block to each variant based on a predefined set of default 751 criteria in VEP. In addition, the "--nearest" option was applied to identify the nearest

753

754755

756

757

758

759

760

761

762

763

764

765766

767

768769

770

771772

773

774

775

776 777

778

779

780

781

782 783

784

785

786

787

788 789 gene with a protein-coding transcription start site (TSS) for variants located in the intergenic region. Genome-wide association analysis in individual Studies The association of the SNPs was analyzed by GWAS in PLINK 2.0, using linear regression for three continuous traits (levels of TSH, FT4, and TPOAb) and logistic regression for five binary phenotypes (subclinical hypothyroidism, isolated hypothyroxinemia, subclinical hyperthyroidism, overt hyperthyroidism, and TPOAb positivity), separately in two cohorts (Baoan and Longgang). The genotype-phenotype association was conducted using an additive genetic model on SNP dosages. Moreover, analyses were adjusted for the gestational week of the thyroid test, maternal age, and the top ten principal components to account for population stratification. **Meta-analysis** We conducted fixed-effect GWAS meta-analyses based on an inverse-variance weighting of Baoan and Longgang using METAL software<sup>[68]</sup>. To visualize the metaanalysis results, we generated a Manhattan plot and a quantile-quantile (QQ) plot with an R script. In terms of interpreting the results of the meta-analysis, we defined the lead SNP as the SNP with the most significant P-value in the single-SNP association test within a 1-Mbp window. A locus was considered to have reached the significance threshold if the lead SNP within that locus had a P-value  $\leq 5 \times 10^{-8}$ . A locus is considered novel locus for the trait if its leading SNP is in linkage equilibrium (LD R<sup>2</sup><0.2) with any known variants (listed in the GWAS Catalog as of December 31, 2023) on the same chromosome. Specifically, using the GWAScatalog database, we obtained all the trait-related known variants located on the same chromosome as our novel lead variants (Triat ID in the Experimental Factor Ontology: TSH: EFO\_0004748, FT4: EFO 0005130, thyroid peroxidase antibody measurement: EFO 0005666, and hyperthyroidism: EFO 0009189)<sup>[69]</sup>. And then, for all of our novel SNPs, we use East Asians (EAS) and Europeans (EUR) populations in the 1000G genome to calculate the linkage disequilibrium R-square between variants we identified and all known SNPs on the same chromosome using LDpair (<a href="https://ldlink.nih.gov/?tab=ldpair">https://ldlink.nih.gov/?tab=ldpair</a>). And the results of linkage disequilibrium R-square between novel variants and known variants are shown in **Table S4A**. **Conditional analysis** 

- 790 Stepwise conditional analyses were performed for the GWAS-meta results to identify
- 791 independent signals that affect TSH and FT4 levels, conditioning on the most
- significant variants (known and novel) identified in our GWAS. After conditioning on
- the lead genome-wide significant variant, variants identified within a 1 MB region of

the variant with a p-value  $< 5.0 \times 10^{-8}$  were considered independent significant

signals. These conditional analyses were repeated, adding in the conditional lead

variants until no variant had a conditional p-value less than the genome-wide

significance ( $P < 5.0 \times 10^{-8}$ ). To determine whether the identified independent

798 significant signals at known loci were independent novel signals, we analyzed East

Asian (EAS) and European (EUR) populations from the 1000 Genomes Project. We

used LDpair (<a href="https://ldlink.nih.gov/?tab=ldpair">https://ldlink.nih.gov/?tab=ldpair</a>) to calculate the linkage

disequilibrium R-square (R2) between the variants we identified and those previously

associated with trait-linked traits. Subsequently, we defined an SNP as an independent

significant signal at a locus if the R<sup>2</sup> was less than 0.2 in both EAS and EUR

populations.

802

803

805 806

810

815

825826

# **Consistency and replication**

To enhance the reproducibility of the findings, we checked internal and external

808 consistency across different datasets. Consistency between the two hospitals involved

809 examining the consistency of the effect direction of the lead SNPs and assessing the

significance of the GWAS P-values in the Baoan and Longgang Studies. On the other

hand, consistency of our meta-GWAS results and external datasets involved

812 examining the consistency in an independent dataset from three separate cohorts

813 (ThyroidOmics Consortium, the GWAS meta-analysis of Alexander T Williams et al.,

the GWAS meta-analysis of M. Medici et al)<sup>[10,11,34]</sup>.

Beyond the participants previously referenced, our research included 4,688

817 individuals who attended Baoan District Maternal and Child Health Hospital for

maternity check-ups during their 40-week gestation. Throughout 2020 and 2021, these

participants underwent non-invasive prenatal testing (NIPT) in the first or second

820 trimester. These samples notably underwent more in-depth sequencing than standard

NIPT, achieving an average depth of 0.3x. The serum levels of TSH, FT4, and

822 TPOAb in NIPT PLUS cohort in were measured by Abott I2000 Immunoassay

823 System with its respective system accessory kit. Using a process similar to Baoan

824 Study, we completed GWAS for thyroid-related traits in the NIPT PLUS cohort.

### eQTL Colocalization analysis

827 Colocalization analyses were performed for novel lead variants using *coloc* R

package<sup>[70]</sup>. Gene expression data from 49 tissues in European ancestry samples

included in the GTEx Project version 8 release were used (https://gtexportal.org/)<sup>[71]</sup>.

630 GWAS data from a region spanning ±1 Mb around each novel SNPs were compiled,

integrated with the corresponding GTEx eQTL data for each specific tissue, and

832 subsequently used as the input for related analyses. Regions that show evidence of

833 colocalization between eQTL and GWAS signals were identified using pre-defined

thresholds: PP4  $\geq$  0.75 and PP4/PP3  $\geq$  3<sup>[70]</sup>. Here, PP4 denotes the posterior

probability of Hypothesis 4, which assesses the likelihood that both the assumed

- model is correct and that the GWAS and expression data are simultaneously
- associated with a single causal variant. PP3 denotes the posterior probability that two
- distinct causal variants exist for GWAS and expression data, respectively. Given the
- 839 genetic structural differences between our East Asian cohort and European
- populations, our findings should be considered an exploratory endeavor.

# **Genetic correlation estimate**

- The meta GWAS summary statistics were used to estimate SNP-based heritability and
- genetic correlation  $(r_g)$  for all phenotypes using LD Score Regression<sup>[36,72]</sup>. GCTA
- was used to calculate LD score files using a deep whole-genome sequencing reference
- 846 panel of 10k Chinese<sup>[36,66,73]</sup>.

#### Mendelian randomization

- Mendelian randomization (MR) is a method for inferring causal associations between
- exposures and outcomes through the use of genetic variants as instrumental variables
- 851 [74]. To avoid bias caused by linkage disequilibrium, we selected the IV (instrumental
- variable) SNPs that reached genome-wide significance in GWAS meta-analysis (P < 5
- 853  $\times 10^{-8}$ ) and achieved independence in linkage disequilibrium (LD)  $r^2 = 0.2$  by GCTA-
- 854 COJO analysis<sup>[75]</sup>. The SNPs with a minor allele frequency (MAF) of <0.01 were
- excluded<sup>[76]</sup>.

841842

847848

856

868

- 857 Since GWAS summary data for maternal and fetal pregnancy outcomes in East Asian
- ancestry is currently unavailable, we conducted Mendelian randomization analyses
- between thyroid-related traits and maternal and fetal pregnancy outcomes using the
- two-sample method within a single cohort [45,77], utilizing the TwoSampleMR package
- after completing our GWAS-meta analysis of the Baoan Study and Longgang
- 862 Study<sup>[78]</sup>. We implemented MR analyses under 3 scenarios:
- 863 (1) Meta-Meta: the two-sample MR method is conducted in one-sample setting;
- 864 (2) Baon-Longgang: Baoan Study served as the source of exposed GWAS data, while the Longgang Study provided the outcome population.
- 866 (3) Longgang-Baoan: Longgang Study served as the source of exposed GWAS data, while the Baoan Study provided the outcome population.
- 869 In order to achieve sufficient power as much as possible, we regard meta-meta as the
- main MR result, and the MR results of the remaining two situations serve as support
- for the meta-meta result.
- The variance of continuous traits explained by variants (R<sup>2</sup>) was estimated using the
- formula  $R^2 = (effect \ size)^2 \times 2 \times MAF \times (1 MAF) / [(effect \ size)^2 \times 2 \times MAF \times (1 MAF)]$
- 875 MAF) +  $(SE)^2 \times 2 \times N \times MAF \times (1 MAF)$ ], where the effect size is measured in
- units of the continuous traits after inverse normal transformation. We calculated the
- F-statistic to evaluate the instrument strength, with values greater than 10 indicating

878 sufficient strength. We applied inverse variance-weighted (IVW), inverse variance-879 weighted using multiplicative random effects (IVWRE), MR-Egger, weighted median (WM) methods, weighted mode, and outlier methods using MR PRESSO<sup>[79]</sup>. If MR 880 881 PRESSO successfully excludes outlier IVs, we re-execute the MR analysis using the 882 new set of IV SNPs. To avoid the effects of the presence of heterogeneity in IVs, the 883 IVWRE method is regarded as the most accurate estimation. 884 885 Maternal and fetal pregnancy outcomes 886 We made full use of relevant data on gestational diabetes and gestational hypertension 887 in our cohort. Because the prevalence of gestational hypertension and preeclampsia 888 was less than 2% in our cohort (gestational hypertension: 0.95% for Longgang and 889 0.47% for Baoan; preeclampsia: 0.42% for Longgang and 1.39% for Baoan), we did 890 not include these two pregnancy complications in our analysis. 891 892 Finally, we included five blood glucose traits (FPG: Fasting Plasma Glucose; HBA1c: 893 Glycated Hemoglobin; OGTT0H: Oral Glucose Tolerance Test at 0 hours; OGTT1H: 894 Oral Glucose Tolerance Test at 1 hour; OGTT2H: Oral Glucose Tolerance Test at 2 895 hours) and two blood pressure traits (SBP: Systolic Blood Pressure; DBP: Diastolic 896 Blood Pressure) in our analysis. We completed the meta-GWAS analyses for these 897 seven quantitative traits and Gestational Diabetes Mellitus (GDM). 898 899 Furthermore, we conducted GWAS and meta-GWAS analyses for six birth outcomes, 900 including gestational duration (birth gestational days), preterm birth (deliveries 901 occurring at less than 37 weeks gestational age), birth weight, birth length, low birth weight (defined as birth weight less than 2500g), and macrosomia (defined as birth 902 weight more than  $4000g)^{[5,80]}$ . For the birth outcomes of birth gestational days and 903 904 preterm birth, we limited the study subjects to mothers who delivered live-born 905 offspring through vaginal delivery. 906 907 Given that some studies have shown that TPOAb positivity with euthyroid is also a risk factor for various pregnancy complications<sup>[1]</sup>, we included euthyroid TPOAb 908 909 positivity as an exposure to our analysis. Therefore, after deciding on the list of IV 910 SNPs, we conducted MR analyses of associations between 9 thyroid-related traits 911 (TSH levels within reference range during pregnancy, FT4 levels within reference 912 range during pregnancy, subclinical hypothyroidism during pregnancy, isolated 913 hypothyroxinemia during pregnancy, overt hyperthyroidism during pregnancy, 914 subclinical hyperthyroidism during pregnancy, TPOAb levels during pregnancy, 915 TPOAb positivity with euthyroid during pregnancy, and TPOAb positivity during

pregnancy) and 14 maternal and neonatal outcomes (GDM, FPG, HBA1c, OGTT0H,

OGTT1H, OGTT2H, SBP, DBP, birth gestational days, preterm birth, birth weight,

birth length, low birth weight, macrosomia).

916

917

921

922

923

924

925

926

927

928

929 930

931

932

933

934935

936

937

938

939

940

941942

943944945

946

947948

949

950

951

952

953

954

955

956

957

958

959

We also used phenotypic associations to explore associations between 9 thyroid traits and 14 maternal and neonatal outcomes. We collected birth outcome data for 92,132 pregnant women with thyroid function test results from two hospitals (**Table S16**). Before performing phenotypic association analyses, we excluded pregnant women with multiple pregnancies, vitro fertilization, and aborted stillbirth outcomes. In the regression analysis of birth length, birth weight, low birth weight, and Macrosomia, we adjusted for fetal sex, BMI, age, and birth gestational days. For the analysis of gestational duration and preterm birth, we adjusted only for fetal sex, maternal BMI, and maternal age. Because the 9 thyroid trait exposures are highly correlated (Figure S17, Table S14), we computed the Bonferroni correction mainly based on the number of outcomes. A Bonferroni correction for the 14 traits (P-value  $\square < \square 0.05/14 \square = 0.0036$ ) was applied on the IVWRE P-value \( \precent{1}\) to define significant results of phenotypic associations and MR. Biobank Japan Study (BBJ) To investigate the potential causal association between thyroid traits during pregnancy and the physical conditions/diseases in older age, we conducted a bidirectional twosample Mendelian randomization study using our GWAS results and datasets from the BioBank Japan Study. The BioBank Japan Study conducted genome-wide association studies for 220 deep phenotypes (including diseases, biomarkers, and medication usage) in a cohort of 179,000 Japanese individuals<sup>[30]</sup>. Approximately 47% of these subjects were women, and the average age of all subjects was over 62 years<sup>[81]</sup>. A Bonferroni correction for the 220 traits (P-value  $\square < \square 0.05/220 \square = 0.00023$ ) was applied on the IVWRE P-value to define significant MR results. Data Availability GWAS summary statistics for the eight thyroid traits investigated can be accessed through the GWAS catalog (Study Accession: GCST90296455- GCST90296462) and GWAS Atlas upon publication, with approval from the Human Genetic Resources Administration of China (HGRAC) (ID: XXX). Researchers can register and gain access to use data. Raw sequencing data have been deposited to the Genome Sequence Archive (GSA) for Human (https://ngdc.cncb.ac.cn/gsa-human/) at the BIG Data Center, Beijing Institute of Genomics, Chinese Academy of Sciences, under the BioProject accession number (GSA-Human: HRA006833), with approval from HGRAC (ID: XXX). In compliance with the regulations of the Ministry of Science and Technology of the People's Republic of China, the raw sequencing data contain information unique to an individual and thus require controlled access. Researchers

960 who are interested in collaboration are welcome to contact Siyang Liu 961 (liusy99@mail.sysu.edu.cn). 962 963 Acknowledgments 964 The study was supported by the Shenzhen Basic Research Foundation 965 (20220818100717002), Guangdong Basic and Applied Basic Research Foundation 966 (2022B1515120080), the National Natural Science Foundation of China (31900487, 967 82203291) and the Shenzhen Health Elite Talent Training Project. Computation of 968 this study was supported by BrightWing High-performance Computing Platform, 969 School of Public Health (Shenzhen) and the National Supercomputing Center in 970 GuangZhou. 971 972 **Author contribution** 973 974 Design, management, or subject recruitment of the individual studies: S. L, F. W, L. 975 X, J. Z, and data curation: J. Z, Y. W, Z. Y, L. H, J. Z, S. H, and genotyping of the 976 individual studies: Y. W, Y. G, Y. L, Z. Y, and statistical methods, analysis, 977 bioinformatics, or interpretation of the results in the individual studies: Y. W, Y. G, S. 978 C, H. Z, Z. Y, X. G; and drafting of manuscript: Y. W, S. L, Y. G, and critical 979 revision of manuscript: all authors. 980 981 **Competing interests** 982 All authors declare no competing financial interests. 983 984 Figure legends 985 986 Figure 1. Schematic design of the study. 987 TSH: thyroid stimulating hormone; FT4: free thyroxine; TPOAb thyroid peroxidase 988 antibody. **BBJ**: BioBank Japan Study. Created with BioRender.com. 989 990 Figure 2. The manhattan plots for GWAS meta-analyses of TSH(A), and FT4(B). 991 The x-coordinate of the SNPs in the plot represents their position on each 992 chromosome when the y-coordinate implies their P-value (-log10 scale) of the 993 association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e., $5 \times 10^{-8}$ ). Genomic loci containing phenotype-994 995 associated variants previously reported in the GWAS catalog are colored in black, 996 while novel loci are colored in red.

999

1000

1001

1002

1003

1004

1005

1006

1007 1008 1009

1010

1011

1012

1013

1014

1015

1016

1017 1018 1019

1020

1021

1022

1023

1024

1025

1026

10271028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

Figure 3. The manhattan plots for GWAS meta-analyses of thyroid dysfunction: subclinical hypothyroidism(A), isolated hypothyroxinemia **(B)**, overt hyperthyroidism(**C**), and subclinical hyperthyroidism(**D**). The x-coordinate of the SNPs in the plot represents their position on each chromosome when the y-coordinate implies their P-value (-log10 scale) of the association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e.,5×10-8). Genomic loci containing phenotypeassociated variants previously reported in the GWAS catalog are colored in black, while novel loci are colored in red. Figure 4. The manhattan plots for GWAS meta-analyses of thyroid autoimmunity: TPOAb levels (A), TPOAb positivity (B). The x-coordinate of the SNPs in the plot represents their position on each chromosome when the y-coordinate implies their P-value (-log10 scale) of the association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e.,5×10-8). Genomic loci containing phenotype-associated variants previously reported in the GWAS catalog are colored in black. Before performing the GWAS analysis, TPOAb levels were natural log-transformed. Figure 5. The association between thyroid-related traits and maternal blood glucose and blood pressure traits during pregnancy: (A)Observational analysis. (B) Bidirectional mendelian randomization. (C) The forest plot of MR results under 3 scenarios between TSH and 5 blood glucose and blood pressure traits. In Figure A, the upper left triangle of each grid indicates the phenotypic association results in the Longgang cohort, while the lower right triangle indicates the phenotypic association results in the Baoan cohort. To facilitate the comparison of effect estimates corresponding to different traits, we converted the absolute values of the estimates of phenotypic associations into Q-quantiles for plotting. Shaded areas indicate that the results of the associations between FPG and each of SHO, OHP, and EUTb(+) are unavailable due to an insufficient number of subjects in Baoan hospital. In Figure B, the upper left triangle of each grid indicates the results of forward MR (thyroid traits as exposure variables), while the lower right triangle indicates reverse MR (thyroid traits as outcome variables). In Figure C, the MR results for three scenarios are shown: (1) Meta-Meta: the twosample MR method is conducted in one-sample setting; (2) Baon-Longgang: Baoan Study served as the source of exposed GWAS data, while the Longgang Study provided the outcome population. (3) Longgang-Baoan: Longgang Study served as the source of exposed GWAS data, while the Baoan Study provided the outcome population.

- 1039 TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within
- reference range during pregnancy; SHO: subclinical hypothyroidism during
- pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt
- hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during
- pregnancy, TPOAb: TPOAb levels, Tb(+): TPOAb positivity during pregnancy and
- 1044 EUTb(+): TPOAb positivity with normal functioning thyroids(ie, euthyroid). SBP:
- systolic blood pressure; DBP: diastolic blood pressure, HBA1c, Glycated hemoglobin;
- 1046 FPG, Fasting plasma glucose, OGTT0H, Oral glucose tolerance test 0 hour; OGTT1H,
- Oral glucose tolerance test 1 hour; OGTT2H, Oral glucose tolerance test 2 hour,
- 1048 GDM, Gestational diabetes mellitus.

- Figure 6. The association between thyroid-related traits during pregnancy and
- birth outcomes: (A)Prospective observational analysis. (B) Mendelian randomization.
- 1053 (C)Mendelian randomization analysis for casual associations between TSH and
- thyroid cancer and between TSH and gestational duration.
- In Figure A, the upper left triangle of each grid indicates the phenotypic association
- results in the Longgang cohort, while the lower right triangle indicates the phenotypic
- association results in the Baoan cohort.
- 1058 In Figure C, TSH and gestational duration are based on summary statistics from the
- meta-analysis of the Baoan and Longgang Study. ( $N_{TSH}=\square$  67,471, and  $N_{gestational\ duration}$
- 1060 = □51,592). The results of the IVW, IVWRE, MR Egger, Simple mode, and Weighted
- mode methods are based on the analysis of the IVs excluded by MR PRESSO. The
- 1062 crosshairs on the plots represent the 95% confidence intervals for each SNP-TSH or
- 1063 SNP-outcome association. IVW, Inverse Variance Weighted; IVWRE, Inverse
- Variance Weighted with Multiplicative Random Effects.
- 1065 TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within
- reference range during pregnancy; SHO: subclinical hypothyroidism during
- pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt
- 1068 hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during
- 1069 pregnancy, TPOAb: TPOAb levels; Tb(+): TPOAb positivity during pregnancy and
- 1070 EUTb(+):TPOAb positivity with normal functioning thyroids(ie, euthyroid).
- 1073 Figure 7. The results of bidirectional mendelian randomization analysis between
- 1074 thyroid-related traits during pregnancy and thyroid-related diseases in middle-
- aged and elderly people.
- 1076 The upper left triangle of each grid indicates the results of forward MR (thyroid traits
- 1077 as exposure variables), while the lower right triangle indicates the results of reverse
- 1078 MR (thyroid traits as outcome variables). Shaded areas indicate that reverse MR
- results with goiter, Hashimoto's thyroiditis, hypothyroidism and thyroid cancer as the
- exposure variable are not available due to insufficient number of IVs.

- 1081 TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within
- reference range during pregnancy; SHO: subclinical hypothyroidism during
- pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt
- hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during
- pregnancy, TPOAb: TPOAb levels, Tb(+): TPOAb positivity during pregnancy and
- 1086 EUTb(+): TPOAb positivity with normal functioning thyroids (ie, euthyroid).

# Reference

- 1092 [1] Alexander E K, Pearce E N, Brent G A, et al. 2017 Guidelines of the American
- 1093 Thyroid Association for the Diagnosis and Management of Thyroid Disease During
- 1094 Pregnancy and the Postpartum[J]. Thyroid, 2017, 27(3): 315-389.
- 1095 [2] De Leo S, Pearce E N. Autoimmune thyroid disease during pregnancy[J]. Lancet
- 1096 Diabetes Endocrinol, 2018, 6(7): 575-586.
- 1097 [3] Dong A C, Stagnaro-Green A. Differences in Diagnostic Criteria Mask the True
- 1098 Prevalence of Thyroid Disease in Pregnancy: A Systematic Review and Meta-
- 1099 Analysis[J]. Thyroid, 2019, 29(2): 278-289.
- 1100 [4] Korevaar T I M, Derakhshan A, Taylor P N, et al. Association of Thyroid Function
- 1101 Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic
- 1102 Review and Meta-analysis [J]. Jama, 2019, 322(7): 632-641.
- 1103 [5] Derakhshan A, Peeters R P, Taylor P N, et al. Association of maternal thyroid
- 1104 function with birthweight: a systematic review and individual-participant data meta-
- analysis[J]. Lancet Diabetes Endocrinol, 2020, 8(6): 501-510.
- 1106 [6] Lee S Y, Cabral H J, Aschengrau A, et al. Associations Between Maternal Thyroid
- 1107 Function in Pregnancy and Obstetric and Perinatal Outcomes[J]. J Clin Endocrinol
- 1108 Metab, 2020, 105(5): e2015-23.
- 1109 [7] Panicker V, Wilson S G, Spector T D, et al. Heritability of serum TSH, free T4 and
- 1110 free T3 concentrations: a study of a large UK twin cohort[J]. Clin Endocrinol (Oxf),
- 1111 2008, 68(4): 652-9.
- 1112 [8] Hansen P S, Brix T H, Sørensen T I, et al. Major genetic influence on the
- regulation of the pituitary-thyroid axis: a study of healthy Danish twins[J]. J Clin
- 1114 Endocrinol Metab, 2004, 89(3): 1181-7.
- 1115 [9] Nolan J, Campbell P J, Brown S J, et al. Genome-wide analysis of thyroid
- 1116 function in Australian adolescents highlights SERPINA7 and NCOA3[J]. Eur J
- 1117 Endocrinol, 2021, 185(5): 743-753.
- 1118 [10] Teumer A, Chaker L, Groeneweg S, et al. Genome-wide analyses identify a role
- 1119 for SLC17A4 and AADAT in thyroid hormone regulation[J]. Nat Commun, 2018,
- 1120 9(1): 4455.
- [11] Williams AT, Chen J, Coley K, et al. Genome-wide association study of thyroid-

- stimulating hormone highlights new genes, pathways and associations with thyroid
- 1123 disease[J]. Nat Commun, 2023, 14(1): 6713.
- 1124 [12] Krassas G E, Poppe K, Glinoer D. Thyroid Function and Human Reproductive
- 1125 Health[J]. Endocrine Reviews, 2010, 31(5): 702-755.
- 1126 [13] Korevaar T I M, Medici M, Visser T J, et al. Thyroid disease in pregnancy: new
- insights in diagnosis and clinical management[J]. Nat Rev Endocrinol, 2017, 13(10):
- 1128 610-622.
- 1129 [14] Porcu E, Medici M, Pistis G, et al. A meta-analysis of thyroid-related traits
- 1130 reveals novel loci and gender-specific differences in the regulation of thyroid
- 1131 function[J]. PLoS Genet, 2013, 9(2): e1003266.
- 1132 [15] Fitzgerald S P, Bean N G, Fitzgerald S P, et al. The application of new concepts
- of the assessment of the thyroid state to pregnant women[J]. Front Endocrinol
- 1134 (Lausanne), 2022, 13: 987397.
- 1135 [16] Cappola A R, Casey B M. Thyroid Function Test Abnormalities During
- 1136 Pregnancy[J]. Jama, 2019, 322(7): 617-619.
- 1137 [17] Liu S, Huang S, Chen F, et al. Genomic Analyses from Non-invasive Prenatal
- 1138 Testing Reveal Genetic Associations, Patterns of Viral Infections, and Chinese
- 1139 Population History[J]. Cell, 2018, 175(2): 347-359.e14.
- 1140 [18] Liu S, Huang S, Liu Y, et al. Utilizing Non-Invasive Prenatal Test Sequencing
- 1141 Data Resource for Human Genetic Investigation[J]. bioRxiv, 2023:
- 1142 2023.12.11.570976.
- 1143 [19] Hershman J M. The role of human chorionic gonadotropin as a thyroid stimulator
- in normal pregnancy[J]. J Clin Endocrinol Metab, 2008, 93(9): 3305-6.
- 1145 [20] Kwak S H, Park Y J, Go M J, et al. A genome-wide association study on thyroid
- function and anti-thyroid peroxidase antibodies in Koreans[J]. Hum Mol Genet, 2014,
- 1147 23(16): 4433-42.
- 1148 [21] Zhan M, Chen G, Pan C M, et al. Genome-wide association study identifies a
- novel susceptibility gene for serum TSH levels in Chinese populations[J]. Hum Mol
- 1150 Genet, 2014, 23(20): 5505-17.
- 1151 [22] Huang L, Bai F, Zhang Y, et al. Preliminary study of genome-wide association
- 1152 identified novel susceptibility genes for thyroid-related hormones in Chinese
- population[J]. Genes Genomics, 2022, 44(8): 1031-1038.
- 1154 [23] Zhou W, Brumpton B, Kabil O, et al. GWAS of thyroid stimulating hormone
- 1155 highlights pleiotropic effects and inverse association with thyroid cancer[J]. Nat
- 1156 Commun, 2020, 11(1): 3981.
- 1157 [24] Thareja G, Belkadi A, Arnold M, et al. Differences and commonalities in the
- 1158 genetic architecture of protein quantitative trait loci in European and Arab
- populations[J]. Hum Mol Genet, 2023, 32(6): 907-916.
- 1160 [25] Chaker L, Razvi S, Bensenor I M, et al. Hypothyroidism[J]. Nature Reviews
- 1161 Disease Primers, 2022, 8(1): 30.
- 1162 [26] Stagnaro-Green A. Thyroid and pregnancy time for universal screening?[J].
- 1163 Nature Reviews Endocrinology, 2017, 13(4): 192-194.


- 1164 [27] Casey B M, Thom E A, Peaceman A M, et al. Treatment of Subclinical
- Hypothyroidism or Hypothyroxinemia in Pregnancy[J]. N Engl J Med, 2017, 376(9):
- 1166 815-825.
- 1167 [28] Lee S Y, Pearce E N. Assessment and treatment of thyroid disorders in pregnancy
- and the postpartum period[J]. Nat Rev Endocrinol, 2022, 18(3): 158-171.
- 1169 [29] Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility
- and pregnancy[J]. Nat Clin Pract Endocrinol Metab, 2008, 4(7): 394-405.
- 1171 [30] Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic
- 1172 associations for 220 human phenotypes[J]. Nat Genet, 2021, 53(10): 1415-1424.
- 1173 [31] Chu X, Pan C M, Zhao S X, et al. A genome-wide association study identifies
- two new risk loci for Graves' disease[J]. Nat Genet, 2011, 43(9): 897-901.
- 1175 [32] Kochi Y, Yamada R, Suzuki A, et al. A functional variant in FCRL3, encoding Fc
- receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities[J].
- 1177 Nat Genet, 2005, 37(5): 478-85.
- 1178 [33] Mamidi M K, Huang J, Honjo K, et al. FCRL1 immunoregulation in B cell
- development and malignancy[J]. Front Immunol, 2023, 14: 1251127.
- 1180 [34] Medici M, Porcu E, Pistis G, et al. Identification of novel genetic Loci associated
- with thyroid peroxidase antibodies and clinical thyroid disease[J]. PLoS Genet, 2014,
- 1182 10(2): e1004123.
- 1183 [35] Antonelli A, Ferrari S M, Corrado A, et al. Autoimmune thyroid disorders[J].
- 1184 Autoimmun Rev, 2015, 14(2): 174-80.
- 1185 [36] Bulik-Sullivan B K, Loh P R, Finucane H K, et al. LD Score regression
- distinguishes confounding from polygenicity in genome-wide association studies[J].
- 1187 Nat Genet, 2015, 47(3): 291-5.
- 1188 [37] Ortiga-Carvalho T M, Chiamolera M I, Pazos-Moura C C, et al. Hypothalamus-
- 1189 Pituitary-Thyroid Axis[J]. Compr Physiol, 2016, 6(3): 1387-428.
- 1190 [38] Wang D, Wan S, Liu P, et al. Relationship between excess iodine, thyroid
- 1191 function, blood pressure, and blood glucose level in adults, pregnant women, and
- lactating women: A cross-sectional study[J]. Ecotoxicol Environ Saf, 2021, 208:
- 1193 111706.
- 1194 [39] Han Y, Wang J, Wang X, et al. Relationship Between Subclinical
- 1195 Hypothyroidism in Pregnancy and Hypertensive Disorder of Pregnancy: A Systematic
- Review and Meta-Analysis[J]. Front Endocrinol (Lausanne), 2022, 13: 823710.
- 1197 [40] Thangaratinam S, Tan A, Knox E, et al. Association between thyroid
- autoantibodies and miscarriage and preterm birth: meta-analysis of evidence[J]. Bmj,
- 1199 2011, 342: d2616.
- 1200 [41] Brent G A. The debate over thyroid-function screening in pregnancy[J]. N Engl J
- 1201 Med, 2012, 366(6): 562-3.
- 1202 [42] Stagnaro-Green A. Clinical guidelines: Thyroid and pregnancy time for
- 1203 universal screening?[J]. Nat Rev Endocrinol, 2017, 13(4): 192-194.
- 1204 [43] Medici M, Peeters R P, Teumer A, et al. The importance of high-quality
- mendelian randomisation studies for clinical thyroidology[J]. Lancet Diabetes

- 1206 Endocrinol, 2019, 7(9): 665-667.
- 1207 [44] Zhang X, Wu P, Chen Y, et al. Does Maternal Normal Range Thyroid Function
- 1208 Play a Role in Offspring Birth Weight? Evidence From a Mendelian Randomization
- 1209 Analysis[J]. Front Endocrinol (Lausanne), 2020, 11: 601956.
- 1210 [45] Minelli C, Del Greco M F, Van Der Plaat D A, et al. The use of two-sample
- methods for Mendelian randomization analyses on single large datasets[J]. Int J
- 1212 Epidemiol, 2021, 50(5): 1651-1659.
- 1213 [46] Fernández Alba J J, Castillo Lara M, Jiménez Heras J M, et al. High First
- 1214 Trimester Levels of TSH as an Independent Risk Factor for Gestational Diabetes
- Mellitus: A Retrospective Cohort Study[J]. J Clin Med, 2022, 11(13).
- 1216 [47] Knight B A, Shields B M, Hattersley A T, et al. Maternal hypothyroxinaemia in
- pregnancy is associated with obesity and adverse maternal metabolic parameters[J].
- 1218 Eur J Endocrinol, 2016, 174(1): 51-7.
- 1219 [48] Haddow J E, Craig W Y, Neveux L M, et al. Free Thyroxine During Early
- Pregnancy and Risk for Gestational Diabetes[J]. PLoS One, 2016, 11(2): e0149065.
- 1221 [49] Giontella A, Lotta L A, Overton J D, et al. Association of Thyroid Function with
- 1222 Blood Pressure and Cardiovascular Disease: A Mendelian Randomization[J]. J Pers
- 1223 Med, 2021, 11(12).
- 1224 [50] Zhou Y, Liu Y, Zhang Y, et al. Identifying Non-Linear Association Between
- Maternal Free Thyroxine and Risk of Preterm Delivery by a Machine Learning
- 1226 Model[J]. Front Endocrinol (Lausanne), 2022, 13: 817595.
- 1227 [51] Soh S B, Aw T C. Laboratory Testing in Thyroid Conditions Pitfalls and
- 1228 Clinical Utility[J]. Ann Lab Med, 2019, 39(1): 3-14.
- 1229 [52] Daramjav N, Takagi J, Iwayama H, et al. Autoimmune Thyroiditis Shifting from
- Hashimoto's Thyroiditis to Graves' Disease[J]. Medicina (Kaunas), 2023, 59(4).
- 1231 [53] Evangelopoulou M E, Alevizaki M, Toumanidis S, et al. Mitral valve prolapse in
- autoimmune thyroid disease: an index of systemic autoimmunity?[J]. Thyroid, 1999,
- 1233 9(10): 973-7.
- 1234 [54] Ellervik C, Roselli C, Christophersen I E, et al. Assessment of the Relationship
- 1235 Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A
- Mendelian Randomization Study[J]. JAMA Cardiol, 2019, 4(2): 144-152.
- 1237 [55] Norton M E, Jacobsson B, Swamy G K, et al. Cell-free DNA analysis for
- noninvasive examination of trisomy[J]. N Engl J Med, 2015, 372(17): 1589-97.
- 1239 [56] Huang S, Liu S, Huang M, et al. The Born in Guangzhou Cohort Study enables
- generational genetic discoveries[J]. Nature, 2024, 626(7999): 565-573.
- 1241 [57] Richardson T G, Sanderson E, Elsworth B, et al. Use of genetic variation to
- 1242 separate the effects of early and later life adiposity on disease risk: mendelian
- 1243 randomisation study[J]. Bmj, 2020, 369: m1203.
- 1244 [58] Andersen S, Pedersen K M, Bruun N H, et al. Narrow individual variations in
- 1245 serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical
- thyroid disease[J]. J Clin Endocrinol Metab, 2002, 87(3): 1068-72.
- 1247 [59] Kuś A, Chaker L, Teumer A, et al. The Genetic Basis of Thyroid Function: Novel

- Findings and New Approaches[J]. J Clin Endocrinol Metab, 2020, 105(6).
- 1249 [60] Writing Committee for Guidelines on Diagnosis and Management Ofthyroid
- 1250 Diseases During Pregnancy and Postpartum; Chinese Society Ofendocrinology C M A.
- 1251 Guideline on diagnosis and management of thyroid diseases during pregnancy and
- postpartum(2 edition)[J]. Chin J Endocrinol Metab, 2019, 35(8).
- 1253 [61] Hartwig T S, Ambye L, Sørensen S, et al. Discordant non-invasive prenatal
- testing (NIPT) a systematic review[J]. Prenat Diagn, 2017, 37(6): 527-539.
- 1255 [62] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
- 1256 transform[J]. Bioinformatics, 2009, 25(14): 1754-60.
- 1257 [63] Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and
- 1258 SAMtools[J]. Bioinformatics, 2009, 25(16): 2078-9.
- 1259 [64] Depristo M A, Banks E, Poplin R, et al. A framework for variation discovery and
- genotyping using next-generation DNA sequencing data[J]. Nat Genet, 2011, 43(5):
- 1261 491-8.
- 1262 [65] Rubinacci S, Ribeiro D M, Hofmeister R J, et al. Efficient phasing and
- imputation of low-coverage sequencing data using large reference panels[J]. Nat
- 1264 Genet, 2021, 53(1): 120-126.
- 1265 [66] Cheng S, Xu Z, Bian S, et al. The STROMICS genome study: deep whole-
- genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal
- 1267 complex genetic and phenotypic interplay[J]. Cell Discov, 2023, 9(1): 75.
- 1268 [67] Cunningham F, Allen J E, Allen J, et al. Ensembl 2022[J]. Nucleic Acids Res,
- 1269 2022, 50(D1): D988-d995.
- 1270 [68] Willer C J, Li Y, Abecasis G R. METAL: fast and efficient meta-analysis of
- genomewide association scans[J]. Bioinformatics, 2010, 26(17): 2190-1.
- 1272 [69] Sollis E, Mosaku A, Abid A, et al. The NHGRI-EBI GWAS Catalog:
- knowledgebase and deposition resource[J]. Nucleic Acids Res, 2023, 51(D1): D977-
- 1274 d985.
- 1275 [70] Giambartolomei C, Vukcevic D, Schadt E E, et al. Bayesian test for
- 1276 colocalisation between pairs of genetic association studies using summary statistics[J].
- 1277 PLoS Genet, 2014, 10(5): e1004383.
- 1278 [71] The Genotype-Tissue Expression (GTEx) project[J]. Nat Genet, 2013, 45(6):
- 1279 580-5.
- 1280 [72] Bulik-Sullivan B, Finucane H K, Anttila V, et al. An atlas of genetic correlations
- across human diseases and traits[J]. Nat Genet, 2015, 47(11): 1236-41.
- 1282 [73] Yang J, Lee S H, Goddard M E, et al. GCTA: a tool for genome-wide complex
- 1283 trait analysis[J]. Am J Hum Genet, 2011, 88(1): 76-82.
- 1284 [74] Geng T, Smith C E, Li C, et al. Childhood BMI and Adult Type 2 Diabetes,
- 1285 Coronary Artery Diseases, Chronic Kidney Disease, and Cardiometabolic Traits: A
- 1286 Mendelian Randomization Analysis[J]. Diabetes Care, 2018, 41(5): 1089-1096.
- 1287 [75] Yang J, Ferreira T, Morris A P, et al. Conditional and joint multiple-SNP analysis
- 1288 of GWAS summary statistics identifies additional variants influencing complex
- 1289 traits[J]. Nat Genet, 2012, 44(4): 369-75, s1-3.

- 1290 [76] Cui Z, Hou G, Meng X, et al. Bidirectional Causal Associations Between
- 1291 Inflammatory Bowel Disease and Ankylosing Spondylitis: A Two-Sample Mendelian
- Randomization Analysis[J]. Front Genet, 2020, 11: 587876.
- 1293 [77] Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports
- systematic causal inference across the human phenome[J]. Elife, 2018, 7.
- 1295 [78] Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
- imprecisely measured traits using GWAS summary data[J]. PLoS Genet, 2017, 13(11):
- 1297 e1007081.

- 1298 [79] Verbanck M, Chen C Y, Neale B, et al. Detection of widespread horizontal
- 1299 pleiotropy in causal relationships inferred from Mendelian randomization between
- 1300 complex traits and diseases[J]. Nat Genet, 2018, 50(5): 693-698.
- 1301 [80] Goldenberg R L, Culhane J F, Iams J D, et al. Epidemiology and causes of
- 1302 preterm birth[J]. Lancet, 2008, 371(9606): 75-84.
- 1303 [81] Nagai A, Hirata M, Kamatani Y, et al. Overview of the BioBank Japan Project:
- 1304 Study design and profile[J]. J Epidemiol, 2017, 27(3s): S2-s8.



**Figure 1. Schematic design of the study. TSH**: thyroid stimulating hormone; **FT4**: free thyroxine; **TPOAb** thyroid peroxidase antibody. **BBJ:** Biobank Japan study.




Figure 2. The Manhattan for GWAS meta-analyses of TSH(A), and FT4(B).

The x-coordinate of the SNPs in the plot represents their position on each chromosome when the y-coordinate implies their P-value ( $-\log 10$  scale) of the association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e., $5\times10^{-8}$ ). Genomic loci containing phenotype-associated variants previously reported in the GWAS catalog are colored in black, while novel loci are colored in red.





Figure 3. The manhattan plots for GWAS meta-analyses of thyroid dysfunction: subclinical hypothyroidism( $\mathbf{A}$ ), isolated hypothyroxinemia ( $\mathbf{B}$ ), overthyperthyroidism( $\mathbf{C}$ ), and subclinical hyperthyroidism( $\mathbf{D}$ ). Figure 2. The Manhattan for GWAS meta-analyses of TSH( $\mathbf{A}$ ), and FT4( $\mathbf{B}$ ).

The x-coordinate of the SNPs in the plot represents their position on each chromosome when the y-coordinate implies their P-value (-log10 scale) of the

association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e.,5×10-8). Genomic loci containing phenotype-associated variants previously reported in the GWAS catalog are colored in black, while novel loci are colored in red.



**Figure 4.** The manhattan plot for GWAS meta-analyses of thyroid autoimmunity: TPOAb levels (A), TPOAb positivity (B). The x-coordinate of the SNPs in the plot represents their position on each chromosome when the y-coordinate implies their P-value (-log10 scale) of the association test. The black dotted horizontal line indicates the significant threshold for the genome-wide association test(i.e.,5×10-8). Genomic loci containing phenotype-associated variants previously reported in the GWAS catalog are colored in black. Before performing the GWAS analysis, TPOAb levels were natural log-transformed.




Figure 5. The association between thyroid-related traits and maternal blood glucose and blood pressure traits during pregnancy: (A)Observational analysis. (B) Bidirectional mendelian randomization. (C)The forest plot of MR results under 3 scenarios between TSH and 5 blood glucose and blood pressure traits.

In Figure A, the upper left triangle of each grid indicates the phenotypic association results in the Longgang cohort, while the lower right triangle indicates the phenotypic association results in the Baoan cohort. To facilitate the comparison of effect estimates corresponding to different traits, we converted the absolute values of the estimates of phenotypic associations into Q-quantiles for plotting.

In Figure B, the upper left triangle of each grid indicates the results of forward MR (thyroid traits as exposure variables), while the lower right triangle indicates reverse MR (thyroid traits as outcome variables).

In Figure C, the MR results for three scenarios are shown: (1) Meta-Meta: the two-sample MR method is conducted in one-sample setting; (2) Baon-Longgang: Baoan Study served as the source of exposed GWAS data, while the Longgang Study provided the outcome population. (3) Longgang-Baoan: Longgang Study served as

the source of exposed GWAS data, while the Baoan Study provided the outcome population.

TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within reference range during pregnancy; SHO: subclinical hypothyroidism during pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during pregnancy, TPOAb: TPOAb levels, Tb(+): TPOAb positivity during pregnancy and EUTb(+): TPOAb positivity with normal functioning thyroids(ie, euthyroid). SBP: systolic blood pressure; DBP: diastolic blood pressure, HBA1c, Glycated hemoglobin; FPG, Fasting plasma glucose, OGTT0H, Oral glucose tolerance test 0 hour; OGTT1H, Oral glucose tolerance test 2 hour, GDM, Gestational diabetes mellitus.




Figure 6. The association between thyroid-related traits during pregnancy and birth outcomes. (A)Prospective observational analysis. (B) Mendelian randomization. (C)Mendelian randomization analysis for casual associations between TSH and thyroid cancer and between TSH and gestational duration.

In Figure A, the upper left triangle of each grid indicates the phenotypic association results in the Longgang cohort, while the lower right triangle indicates the phenotypic association results in the Baoan cohort.

In Figure C, TSH and gestational duration are based on summary statistics from the meta-analysis of the Baoan and Longgang Study. ( $N_{TSH}=\Box$  67,471, and  $N_{gestational\ duration}$  = $\Box$  51,592). The results of the IVW, IVWRE, MR Egger, Simple mode, and Weighted mode methods are based on the analysis of the IVs excluded by MR PRESSO. The

crosshairs on the plots represent the 95% confidence intervals for each SNP-TSH or SNP-outcome association. IVW, Inverse Variance Weighted; IVWRE, Inverse Variance Weighted with Multiplicative Random Effects.

TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within reference range during pregnancy; SHO: subclinical hypothyroidism during pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during pregnancy, TPOAb: TPOAb levels; Tb(+): TPOAb positivity during pregnancy and EUTb(+):TPOAb positivity with normal functioning thyroids(ie, euthyroid).




Figure 7. The results of bidirectional mendelian randomization analysis between thyroid traits during pregnancy and thyroid-related diseases in middle-aged and elderly people.

The upper left triangle of each grid indicates the results of forward MR (thyroid traits as exposure variables), while the lower right triangle indicates the results of reverse MR (thyroid traits as outcome variables).

TSH: TSH levels within reference range during pregnancy; FT4: FT4 levels within reference range during pregnancy; SHO: subclinical hypothyroidism during pregnancy; ISH: isolated hypothyroxinemia during pregnancy, OHP: overt hyperthyroidism during pregnancy; SHP: subclinical hyperthyroidism during pregnancy, TPOAb: TPOAb levels, Tb(+): TPOAb positivity during pregnancy and EUTb(+): TPOAb positivity with normal functioning thyroids (ie, euthyroid).